Biomass
$1.70
+6%
Broad Spectrum Distillate
$3,000.00
+3%
CBD Isolate
$1,100.00
+0%
CBG Isolate
$6,000.00
-7%
Water Soluble CBD Isolate
$2,300.00
+5%
Water Soluble CBD Broad Spectrum
$2,800.00
+2%
Back to news
19. February 2020
Global Medical News

New Study Supports the Potential for CBD Oil for Patients with Drug-Resistant Epilepsy

Results of a new study on the treatment of CBD (RSHO-X™) oil for drug-resistant epilepsy in children and adolescents are promising after demonstrating good efficacy and tolerability.

Medical Marijuana, Inc. (OTC: MJNA) has announced that a clinical study conducted in Mexico using its Real Scientific Hemp Oil-X™ cannabidiol (CBD) oil has been completed and published in the EC Neurology (ECNE), an internationally peer-reviewed journal that publishes articles related to worldwide research in neuroscience.

“We are encouraged by the study’s results and look forward to understanding more about CBD’s potential effects as we continue to conduct research on this topic,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “There are many people who are already using our products to experience a variety of health and wellness benefits. We believe that with the added assurance of these results, there will be many other people who may take interest in our products.”

The treatment yielded a positive effect on seizure reduction after 3 months. Most of the children 25/37 (67.5%) reported a reduction in seizure frequency; a 100% reduction in 1 (2.2%), more than 80% reduction in 11 (25%), 50% or more in 25 (67.5%) and less than 50% reduction was reported in 12 (27.2%) patients, respectively.

“For many children, there are countless pharmaceutical drugs that either don’t work for them or produce a variety of harmful side effects,” said Dr. Carlos G. Aguirre-Velázquez, a globally recognized pediatric neurologist and lead researcher on the study. “We are optimistic that this study will be one of many that showcases the potential for hemp CBD oil to be safe and useful.”

Medical Marijuana is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® BiotechnologiesInc. and Kannalife, Inc.